In COPD patients, concurrent use of inhaled beta-agonists and muscarinic antagonists was associated with reduced heart rate variability (SDNN beta coefficient -3.980, p=0.019).
Cross-Sectional (n=79)
Does heart rate variability measured by a wearable biosensor correlate with disease severity, bronchodilator therapy, and patient-reported outcomes in patients with COPD?
In COPD patients, reduced HRV measured by a wearable biosensor is associated with concurrent use of inhaled beta-agonists and muscarinic antagonists, and correlates with worse health status and performance measures.
Effect estimate: beta coefficient -3.980
p-value: p=0.019
The purpose of this study was to explore the relationships between heart rate variability (HRV) and various phenotypic measures that relate to health and functional status in chronic obstructive pulmonary disease (COPD), and secondly, to demonstrate the feasibility of ascertaining HRV via a chest-worn wearable biosensor in COPD patients. HRV analysis was performed using SDNN (standard deviation of the mean of all normal R-R intervals), low frequency (LF), high frequency (HF), and LF/HF ratio. We evaluated the associations between HRV and COPD severity, class of bronchodilator therapy prescribed, and patient reported outcomes. Seventy-nine participants with COPD were enrolled. There were no differences in SDNN, HF, and LF/HF ratio according to COPD severity. The SDNN in participants treated with concurrent beta-agonists and muscarinic antagonists was lower than that in other participants after adjusting heart rate (beta coefficient −3.980, p = 0.019). The SDNN was positively correlated with Veterans Specific Activity Questionnaire (VSAQ) score (r = 0.308, p = 0.006) and handgrip strength (r = 0.285, p = 0.011), and negatively correlated with dyspnea by modified Medical Research Council (mMRC) questionnaire (r = −0.234, p = 0.039), health status by Saint George’s Respiratory Questionnaire (SGRQ) (r = −0.298, p = 0.008), symptoms by COPD Assessment Test (CAT) (r = −0.280, p = 0.012), and BODE index (r = −0.269, p = 0.020). When measured by a chest-worn wearable device, reduced HRV was observed in COPD participants receiving inhaled beta-sympathomimetic agonist and muscarinic antagonists. HRV was also correlated with various health status and performance measures.
Park et al. (Tue,) conducted a cross-sectional in Chronic Obstructive Pulmonary Disease (n=79). Concurrent beta-agonists and muscarinic antagonists vs. Other participants was evaluated on SDNN (standard deviation of the mean of all normal R-R intervals) (beta coefficient -3.980, p=0.019). In COPD patients, concurrent use of inhaled beta-agonists and muscarinic antagonists was associated with reduced heart rate variability (SDNN beta coefficient -3.980, p=0.019).